Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT04561739
Other study ID # CAGE-FREE 1
Secondary ID
Status Active, not recruiting
Phase N/A
First received
Last updated
Start date February 1, 2021
Est. completion date May 5, 2027

Study information

Verified date March 2024
Source Xijing Hospital
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The introduction of Bare-metal stents (BMS) since 1986 has alleviated the limitations of plain old balloon angioplasty (POBA) related elastic recoil and flow-limiting dissections. Later on, higher restenosis rates due to exaggerated neointimal growth in BMS has led to the development of drug-eluting stents (DES), which elutes an antiproliferative drug to the vessel wall and reduce the restenosis rate. However, late stent thrombosis and restenosis, with a hazard of nearly 2% per year after implantation, remained a concern and motivated the development of drug-coated balloons (DCB). The advantages of DCB are that leaving no metal in the blood vessel and respect the vessel anatomy. Recently, studies with the strategy of DCB angioplasty with bailout stenting have demonstrated safety and efficacy for the small-vessel disease. In the BASKET-SMALL 2 trial, which compared SeQuent Please DCB with EES or Taxus DES in the vessels that have reference diameter<3mm, showed that at 12-month follow-up, DCB was non-inferior to DES (MACE [cardiac death, non-fatal myocardial infarction, and target-vessel revascularisation] rates: 8% vs. 9%). Although some small-scale RCT using surrogate endpoints have reported that no significant difference in MLD or late lumen loss between the two groups in large vessels, up to now, there is no large-scale RCT comparing the clinical outcomes of DCB versus DES in large vessels with de novo lesions. Therefore, the investigators hypothesized that in patients undergoing non-complex percutaneous coronary intervention (PCI) for de-novo stenoses, drug-coated balloon (DCB) is non-inferior to drug-eluting stents (DES).


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 2272
Est. completion date May 5, 2027
Est. primary completion date May 5, 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: 1. Patients with an indication for PCI due to acute or chronic coronary syndrome 2. Patients with de-novo, non-complex lesion* and underwent successful pre-dilation** 3. Patients who are able to complete the follow-up and compliant to the prescribed medication - Non-complex PCI is defined as 1. Vessels treated<3; stents implanted<3; lesions treated<3 or Total stent length<60 mm 2. Bifurcation does not require 2 stents 3. Non left main lesion 4. Non venous or arterial graft lesion 5. Non chronic total occlusion lesion 6. Do not require the use of atherectomy device **Successful pre-dilation is defined as fulfilling all the following criteria 1. Thrombolysis In Myocardial Infarction [TIMI] flow =3 2. Without dissections type D, E, and F 3. Residual stenoses <30% after balloon pre-dilation (visual). 4. Without serious complication requiring the termination of PCI Exclusion Criteria: 1. Under the age of 18 2. Unable to give informed consent 3. The patient is a woman who is pregnant or nursing (a pregnancy test must be performed within 7 days prior to the index procedure in women of child-bearing potential according to local practice) 4. Known contraindication to medications such as Heparin, antiplatelet drugs, or contrast. 5. Currently participating in another trial and not yet at its primary endpoint 6. The concurrent medical condition with a life expectancy of less than 2 years 7. Previous intracranial hemorrhage 8. In-stent stenosis requiring revascularization (defined as stenosis=50% by visual or positive functional assessments in any vessel) 9. Atrial fibrillation 10. Prior CABG 11. Cardiogenic shock

Study Design


Related Conditions & MeSH terms


Intervention

Device:
Paclitaxel coated balloon
The Paclitaxel coated balloon is a paclitaxel-eluting rapid exchange balloon catheter for PTCA. Paclitaxel is the pharmacologically active substance for anti-neointima, whereas iopromide, a well-tolerated nonionic x-ray contrast agent, acts as a release-supporting additive. The active drug coating is located on the surface of the balloon, which contains 3 µg Paclitaxel per 1 mm2. The spray coating of the mixture of paclitaxel and iopromide of the Swide is via ultrasound, with the crystal size<2um.
Sirolimus eluting stents
The device has a backbone of L605 cobalt chromium. The stent has a open cell, in-phase, peak-to-valley design. The strut thickness is 86 µm and has a stent profile less than 1.12mm. The polymer coating of the stent is a styrene-butadiene block copolymer. The antiproliferative drug concentration is at 9 ug/mm, which 80% of the drug is released by 30 days.

Locations

Country Name City State
China Ling Tao Xi'an Shannxi

Sponsors (1)

Lead Sponsor Collaborator
Xijing Hospital

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Device-oriented Composite Endpoint (DoCE) DoCE is a composite clinical endpoint of Cardiac cause death, Target vessel myocardial infarction (TV-MI), and Clinically and physiologically indicated target lesion revascularization (CI-TLR). 24 months
Secondary Device-oriented Composite Endpoint (DoCE) Rates of the DoCE beside the time point of primary endpoint 1, 12, 36, and 60 months
Secondary Cardiac cause death Rates of individual components of the DoCE 1, 12, 24, 36, and 60 months
Secondary Target vessel myocardial infarction (TV-MI) Rates of individual components of the DoCE 1, 12, 24, 36, and 60 months
Secondary Clinically and physiologically indicated target lesion revascularization (CI-TLR) Rates of individual components of the DoCE 1, 12, 24, 36, and 60 months
Secondary Patient-oriented composite endpoint (PoCE) Patient-oriented composite endpoint (PoCE) defined as all-cause death, any stroke, any MI, and any clinically and indicated revascularisation) 1, 12, 24, 36, and 60 months
Secondary All-cause death individual components of PoCE 1, 12, 24, 36, and 60 months
Secondary Any MI individual components of PoCE 1, 12, 24, 36, and 60 months
Secondary Any stroke individual components of PoCE 1, 12, 24, 36, and 60 months
Secondary Any revascularisation individual components of PoCE 1, 12, 24, 36, and 60 months
Secondary Any clinically and physiologically indicated revascularisation 1, 12, 24, 36, and 60 months
Secondary Target vessel failure (TVF) Target vessel failure, defined as cardiovascular death, TV MI and clinically-indicated target vessel revascularisation 1, 12, 24, 36, and 60 months
Secondary Clinical and physiologically indicated target vessel revascularization 1, 12, 24, 36, and 60 months
Secondary Net adverse clinical events (NACE) Net adverse clinical events (NACE), define as POCE or BARC type 3 or 5 bleeding events 1, 12, 24, 36, and 60 months
Secondary BARC type 3 or 5 bleeding events 1, 12, 24, 36, and 60 months
Secondary BARC defined type 2, 3 or 5 bleeding events 1, 12, 24, 36, and 60 months
Secondary Definite/Probable Stent thrombosis rates According to ARC-II classification 1, 12, 24, 36, and 60 months
Secondary Device success Device success is defined by the following: DCB: 1.Successful delivery within 120 seconds (DCB in vessel) of the DCB device at the intended target lesion; 2.DCB is successfully dilated for at least 30 seconds and the device system is successfully withdrawn; 3.After DCB dilation, the target vessel has no flow limiting dissection (type D, E and F); and the final in-lesion residual stenosis is less than 30% by core laboratory QCA (preferred methodology) or visual assessment; 4.No bailout procedure by stent; DES: 1.1. Successful delivery, balloon expansion, and deployment of the first assigned device, at the intended target lesion; 2.Successful withdrawal of the device delivery system; 3. 3. Attainment of a final in-stent residual stenosis of <20% by core laboratory QCA (preferred methodology) or visual assessment; 0 day (during index PCI)
Secondary Procedure success during PCI Device success + without the occurrence of DoCE + no stent thrombosis at discharge during the index procedure hospital stay (maximum of 7 days). 7 days
Secondary Clinically relevant ischemic or bleeding events Time from randomization to the occurrence of first any ischemic or bleeding endpoints, including all-cause death, any stroke, MI, BARC-defined type 3 bleeding, any revascularization and BARC-defined type 2 bleeding events 1, 12, 24, 36, and 60 months
See also
  Status Clinical Trial Phase
Recruiting NCT06030596 - SPECT Myocardial Blood Flow Quantification for Diagnosis of Ischemic Heart Disease Determined by Fraction Flow Reserve
Completed NCT04080700 - Korean Prospective Registry for Evaluating the Safety and Efficacy of Distal Radial Approach (KODRA)
Recruiting NCT03810599 - Patient-reported Outcomes in the Bergen Early Cardiac Rehabilitation Study N/A
Recruiting NCT06002932 - Comparison of PROVISIONal 1-stent Strategy With DEB Versus Planned 2-stent Strategy in Coronary Bifurcation Lesions. N/A
Not yet recruiting NCT06032572 - Evaluation of the Safety and Effectiveness of the VRS100 System in PCI (ESSENCE) N/A
Recruiting NCT04242134 - Drug-coating Balloon Angioplasties for True Coronary Bifurcation Lesions N/A
Recruiting NCT05308719 - Nasal Oxygen Therapy After Cardiac Surgery N/A
Completed NCT04556994 - Phase 1 Cardiac Rehabilitation With and Without Lower Limb Paddling Effects in Post CABG Patients. N/A
Recruiting NCT05846893 - Drug-Coated Balloon vs. Drug-Eluting Stent for Clinical Outcomes in Patients With Large Coronary Artery Disease N/A
Recruiting NCT06027788 - CTSN Embolic Protection Trial N/A
Recruiting NCT05023629 - STunning After Balloon Occlusion N/A
Completed NCT04941560 - Assessing the Association Between Multi-dimension Facial Characteristics and Coronary Artery Diseases
Completed NCT04006288 - Switching From DAPT to Dual Pathway Inhibition With Low-dose Rivaroxaban in Adjunct to Aspirin in Patients With Coronary Artery Disease Phase 4
Completed NCT01860274 - Meshed Vein Graft Patency Trial - VEST N/A
Recruiting NCT06174090 - The Effect of Video Education on Pain, Anxiety and Knowledge Levels of Coronary Bypass Graft Surgery Patients N/A
Completed NCT03968809 - Role of Cardioflux in Predicting Coronary Artery Disease (CAD) Outcomes
Terminated NCT03959072 - Cardiac Cath Lab Staff Radiation Exposure
Recruiting NCT05065073 - Iso-Osmolar vs. Low-Osmolar Contrast Agents for Optical Coherence Tomography Phase 4
Recruiting NCT04566497 - Assessment of Adverse Outcome in Asymptomatic Patients With Prior Coronary Revascularization Who Have a Systematic Stress Testing Strategy Or a Non-testing Strategy During Long-term Follow-up. N/A
Completed NCT05096442 - Compare the Safety and Efficacy of Genoss® DCB and SeQuent® Please NEO in Korean Patients With Coronary De Novo Lesions N/A